Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Announcement: 6th annual Marketing Excellence Japan 2013 – Hilton Tokyo, May 14 – 15
April 1, 2013
- Dainippon Sumitomo Pharma Ties Up with Venture Company to Commercialize iPS Cell Therapy for Retinal Disease
April 1, 2013
- EMA Accepts Shionogi’s MAA for Ospemifene
April 1, 2013
- Asklep to Establish Joint Venture Company with US CRO ReSearch Pharmaceutical Services
April 1, 2013
- GSK's Operating Profit Down 22% in 2012 due to Cervarix Sales Drop
March 29, 2013
- Takeda Files NDA for Fixed-Dose Combination of Takepron, Low-Dose Aspirin in Japan
March 29, 2013
- Takeda Files NDAs for Cell Culture-Based New Flu Vaccines
March 29, 2013
- Shionogi Settles Crestor Lawsuit in US
March 28, 2013
- Equa Tops February Detailing Ranking in GP, HP Markets, Driven by Expanded Concurrent Use: Rep Track Survey
March 28, 2013
- First Time NDA Filed in Japan for Meningococcal Vaccine: Sanofi
March 28, 2013
- Otsuka, Lundbeck to Jointly Develop, Market Alzheimer’s Disease Drug
March 28, 2013
- AnGes Licenses Nucleic Acid Drug for Diseases Causing Lower Back Pain to Nippon Zoki in Japan
March 28, 2013
- Takeda, Novartis Rank 1st in Total Average Score with Favorable Impression on Quality of Development: IAL Survey
March 28, 2013
- Concurrent-Use Indications Approved for Trazenta: NBI, Eli Lilly Japan
March 27, 2013
- ASKA Targets Sales of 50 Billion yen in FY2015, Up 20% vs. FY2012 Outlook: 3-Year Plan
March 27, 2013
- New Parkinson’s Disease Treatment Nouriast Approved: Kyowa Kirin
March 27, 2013
- FD Treatment Acofide Approved: Zeria, Astellas
March 27, 2013
- Otsuka Receives Approval for DPP-4 Inhibitor Onglyza, to Transfer Marketing Rights to Kyowa Kirin
March 27, 2013
- Takeda Announces Full Cancellation of Correction Notice Based on Transfer Pricing Tax System; 15.2 Billion Yen Refund Expected
March 27, 2013
- Marc Dunoyer Steps Down as Chairman of GSK K.K.
March 26, 2013
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…